ClinicalTrials.gg
RecruitingNCT07542210SECUREUpdated Oct 16, 2026

Barriers and Facilitators of Persistence With Adjuvant Osimertinib

An observational study in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 26 open to participants now, 79 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Planned enrollment
53rd of 67
100 · median 350
Started
2026
with 8 others
Observational
67 of 210
10 open now
Primary completion
2026-10
later than 36 of 78 live
Registered
206th of 210
by date

Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 53rd largest by planned enrollment of the 67 observational ones that give a count, is one of 9 that started in 2026, is one of 67 observational ones, reaches primary completion later than 36 of the 78 other live ones, and was the 206th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

26 of the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 participants will be enrolled, comprising around 85 patients and 15 physicians. All participants will be interviewed online or in-person using a COM-B (Capability, Opportunity, Motivation - Behaviour) based guide. Interviews will be conducted in waves, recorded, transcribed, and analysed using both deductive and inductive methods.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Include adult patients with early-stage NSCLC who received adjuvant osimertinib after curative surgery, as well as physicians experienced in prescribing adjuvant osimertinib.

Eligibility criteria

For patient

Inclusion Criteria:

  • Adults (≥18 years) with NSCLC who have received osimertinib as the 3rd generation EGFR-TKI therapy and meet one of the following: Patients who received adjuvant osimertinib for less than 34 months and discontinued treatment (off treatment), or Patients who received adjuvant osimertinib for at least 34 months (either off treatment or still on treatment).
  • For off treatment patients, discontinuation or completion of osimertinib is required to occur within 6 months by screening.
  • Willing and able to provide , participate in an online or in-person qualitative interview, and permit audio recording for research purposes.

Exclusion Criteria:

  • Prior receipt of 3rd generation EGFR-TKI as adjuvant therapy as part of any interventional clinical trial.
  • Prior receipt of 1st generation EGFR-TKIs as adjuvant therapy.
  • Evidence of cognitive impairment that would likely to interfere with participation in an interview, as informally assessed during screening.
  • Unaware of or do not understand their own medical condition.

For physicians

Inclusion Criteria:

  • Licensed medical oncologists, thoracic surgeons, or pulmonologists with experience of prescribing osimertinib as adjuvant treatment and actively managing patients who will participate the interview.
  • Managed 5 patients with early-stage NSCLC receiving osimertinib within the past 6 months.
  • Holding a professional title equivalent to or higher than attending physician.
  • Willing and able to provide informed consent, participate in an online or in-person qualitative interview, and permit audio recording for research purposes.

Exclusion Criteria:

  • Unable or unwilling to follow study procedures.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Interview-Physicians

    Interview the physicians experienced in prescribing osimertinib and managing osimertinib-treated patients

  • Interview-Patients

    Interview the Patients with treated with osimertinib for less 6 months, 6-18 months, 18-34 months, more than 34 months

This study also gives OsimertinibStudies of OsimertinibOsimertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Barriers to persistence

    to identify factors that prevent patients from maintaining persistence to osimertinib adjuvant treatment. Barriers may include adverse effects, logistical challenges, financial constraints, psychosocial issues, communication gaps, etc.

    Time frame: Day of interview completion

  2. Facilitators of persistence

    to determine factors that support patients in continuing osimertinib adjuvant treatment. Facilitators may include perceived efficacy, effective management of side effects, strong physician-patient communication, practical supports, family or peer encouragement, etc.

    Time frame: Day of interview completion

Secondary outcomes

  1. Barriers and facilitators of persistence in different treatment duration cohorts

    Barriers and facilitators of persistence in different treatment duration cohorts.

    Time frame: Day of interview completion

  2. Support needed by patients during their long-term treatment journey

    Support needed by patients during their long-term treatment journey: to highlight what additional information, tools, or services patients feel would help sustain persistence

    Time frame: Day of interview completion

07

Study locations

1 of 1 sites recruiting
  • Research Site
    Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
Aug 13, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07542210
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Aug 13, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion